Biographical Sketch
Stewart Lyman, Ph.D, has
over 32 years’ experience in research and biotechnology.
In 2004 he started Lyman BioPharma Consulting LLC to
offer two primary services: (1) advice on how to set up
and run successful collaborations with outside
investigators, either academic or in industry; (2)
technology and science assessment, with a special focus
on developing agonists and antagonists for tyrosine
kinase and other receptors.
Dr. Lyman joined Immunex Corporation in 1988 as a
molecular biologist and continuously assumed greater
scientific responsibility during his 14 year tenure.
Within a year of joining the company he initiated the
largest research project in Immunex's history, Receptors
in Search of Ligands (RISOL). The RISOL project cloned
eight unique cytokines/growth factors, thanks to Dr.
Lyman’s insight that cloned receptors could be used as
tools to identify their unknown ligands. Subsequently Dr.
Lyman chaired numerous projects at Immunex in signal
transduction, molecular biology, and hematology/oncology.
Dr. Lyman has cloned several growth factors, including
Ephrin B1 and human TSLP, and has identified ligands for
CD7, CD44, and the c-kit
tyrosine
kinase receptor. His most significant scientific
accomplishment was cloning flt3 ligand, an early acting
hematopoietic growth factor and key regulator of
dendritic cell proliferation. After designing the
clinical form of flt3, he helped lead flt3 into clinical
trials for stem cell mobilization and cancer
immunotherapy.
In 1998, Dr. Lyman joined the Immunex Scientific
Management Team as Director of Extramural Research, and
for the next four years ran the largest extramural
research program in the United States. His group managed
more than 2500 research collaborations, shipping over
1000 distinct reagents to over 1000 scientific and
industrial groups at institutions worldwide. He was also
responsible for the initial review of all in-licensing
opportunities. As Director, he developed an innovative
system for timely collection, distribution, and storage
of data from collaborators, and his emphasis on
inspecting collaborators’ data for intellectual property
opportunities significantly expanded Immunex’s patent
portfolio.
Dr. Lyman holds 21 U.S. patents and has authored or
co-authored 129 scientific
publications as well as numerous
articles on collaboration
management and
Op-Ed pieces
on
biotechnology issues. He has been invited to
give presentations
about
cytokines and their receptors at numerous national and
international meetings. He served on the scientific
advisory board of Modern Drug
Discovery magazine and is a
member of the AAAS.
Dr. Lyman received his B.S. degree from the State
University of New York at Albany and his Doctorate in
Oncology from the McArdle Laboratory for Cancer Research
at the University of Wisconsin-Madison. Prior to joining
Immunex he conducted postdoctoral research at the Fred
Hutchinson Cancer Research Center in Seattle.